Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis

被引:6
|
作者
Hagglund, H. [1 ,2 ,3 ]
Sander, B. [2 ,4 ]
Ahmadi, A. [4 ]
Gulen, T. [2 ,5 ,6 ]
Nilsson, G. [2 ,6 ]
机构
[1] Karolinska Univ Hosp Huddinge, Dept Hematol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Mastocytosis Ctr Karolinska, S-17176 Stockholm, Sweden
[3] Uppsala Univ, Univ Uppsala Hosp, Dept Med Sci, Div Hematol, Uppsala, Sweden
[4] Karolinska Univ Hosp Huddinge, Dept Pathol, Stockholm, Sweden
[5] Karolinska Univ Hosp Huddinge, Dept Resp Med & Allergy, Stockholm, Sweden
[6] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, S-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Mastocytosis; Mast cell; BRAF; Mutation; RENAL-CELL CARCINOMA; DOSE-RESPONSE METAANALYSIS; COLORECTAL-CANCER RISK; DIETARY FIBER; PROSTATE-CANCER; PHYSICAL-ACTIVITY; COHORT; PATTERNS; EPIDEMIOLOGY; DISEASE;
D O I
10.1007/s12032-014-0123-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most patients with systemic mastocytosis (SM) carry a D816 V KIT mutation causing a ligand-independent activation of the receptor. Down-stream of KIT is several components known to be mutated in different malignancies. RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cell leukemias (HCL) and half of malignant melanomas. We investigated BRAF mutations in 36 subjects with different forms of SM, but could not detect BRAF mutation in any of the cases, not even in the mast cell lineage of a patient with V600E BRAF-positive HCL. Thus, although BRAF is commonly mutated it appears not to be present in SM.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+systemic mastocytosis: a preclinical study
    Degenfeld-Schonburg, Lina
    Gamperl, Susanne
    Stefanzl, Gabriele
    Schruef, Anna-Katharina
    Sadovnik, Irina
    Bauer, Karin
    Smiljkovic, Dubravka
    Eisenwort, Gregor
    Peter, Barbara
    Greiner, Georg
    Hadzijusufovic, Emir
    Schwaab, Juliana
    Sperr, Wolfgang R.
    Hoermann, Gregor
    Kopanja, Sonja
    Szepfalusi, Zsolt
    Hoetzenecker, Konrad
    Jaksch, Peter
    Reiter, Andreas
    Arock, Michel
    Valent, Peter
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (02): : 355 - 378
  • [42] Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
    Si, Lu
    Kong, Yan
    Xu, Xiaowei
    Flaherty, Keith T.
    Sheng, Xinan
    Cui, Chuanliang
    Chi, Zhihong
    Li, Siming
    Mao, Lili
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) : 94 - 100
  • [43] A change in structural integrity of c-Kit mutant D816V causes constitutive signaling
    Raghav, Pawan Kumar
    Singh, Ajay Kumar
    Gangenahalli, Gurudutta
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2018, 808 : 28 - 38
  • [44] Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
    Park, Charny
    Ha, Sang Yun
    Kim, Seung Tae
    Kim, Hee Cheol
    Heo, Jin Seok
    Park, Young Suk
    Lauwers, Gregory
    Lee, Jeeyun
    Kim, Kyoung-Mee
    ONCOTARGET, 2016, 7 (04) : 4024 - 4035
  • [45] BRAF V600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
    Ehlers, Margret
    Schmidt, Mathias
    Mattes-Gyorgy, Katalin
    Antke, Christina
    Enczmann, Juergen
    Schlensog, Martin
    Japp, Anna
    Haase, Matthias
    Allelein, Stephanie
    Dringenberg, Till
    Giesel, Frederik
    Esposito, Irene
    Schott, Matthias
    HORMONE AND METABOLIC RESEARCH, 2022, 54 (12) : 852 - 858
  • [46] Determination of the mutation BRAF V600E in melanoma patients Uruguayans
    Eugenia Mazzei, Maria
    Hochmann, Jimena
    Manrique, Gonzalo
    Luisa Marino, Ana
    Delgado, Lucia
    Martinez Asuaga, Miguel
    REVISTA MEDICA DEL URUGUAY, 2013, 29 (02): : 97 - 102
  • [47] Utility of BRAF V600E immunohistochemistry in the diagnosis of mandibular ameloblastomas
    Ji, Y. D.
    Johnson, D. N.
    Faquin, W. C.
    Peacock, Z. S.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2024, 53 (02) : 122 - 126
  • [48] BRAF V600E Mutational Status in Pediatric Thyroid Cancer
    Henke, Lauren E.
    Perkins, Stephanie M.
    Pfeifer, John D.
    Ma, Changquing
    Chen, Yumei
    DeWees, Todd
    Grigsby, Perry W.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (07) : 1168 - 1172
  • [49] Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma
    Li, Yuanyuan
    Umbach, David M.
    Li, Leping
    MELANOMA RESEARCH, 2017, 27 (06) : 527 - 535
  • [50] Braf V600E mutation in melanoma: translational current scenario
    J. A. Guadarrama-Orozco
    A. Ortega-Gómez
    E. B. Ruiz-García
    H. Astudillo-de la Vega
    A. Meneses-García
    C. Lopez-Camarillo
    Clinical and Translational Oncology, 2016, 18 : 863 - 871